Analysis of Centers for Disease Control and Prevention criteria for the eosinophilia-myalgia syndrome in a geographically defined population

Journal of Rheumatology

Volumn 23, Issue SUPPL. 46, 1996, Pages 73-80

  Spitzer, Walter O ^a,b   Haggerty, Jeannie L ^a,b   Berkson, Laeroa ^a,c   Davis, William ^a   Palmer, Wilfred ^a,d   Tamblyn, Robyn ^a,b   Laprise, Rejean ^a,b   Mulder, Lizbeth J ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b Dept of Epidemiol and Biostatist ^*  (Canada)

^c Division of Rheumatology

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

case con trol study; criteria; diagnosis; eosinophilia myalgia syndrome; pharmacoepidemiology; surveillance

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; BENZODIAZEPINE; CORTICOSTEROID; GOLD SALT; HYDROCHLOROTHIAZIDE; HYDROXYCHLOROQUINE; NONSTEROID ANTIINFLAMMATORY AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; VITAMIN;

CASE STUDY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EOSINOPHILIA MYALGIA SYNDROME; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; ADULT; ARTICLE; CANADA; MIDDLE AGED; PATIENT SELECTION; PREVALENCE; PUBLIC HEALTH SERVICE; UNITED STATES;

ADULT; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); EOSINOPHILIA-MYALGIA SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; ONTARIO; PATIENT SELECTION; PREVALENCE; QUEBEC; TRYPTOPHAN; UNITED STATES;

EID: 0030255428     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Centers for Disease Control and Prevention: Eosinophilia-myalgia syndrome - New Mexico. MMWR Morb Mortal Wkly Rep 1989;38:765-7.
2. Centers for Disease Control and Prevention: Eosinophilia-myalgia syndrome and L-tryptophan-containing products - New Mexico, Minnesota, Oregon and New York, 1989. MMWR Morb Mortal Wkly Rep 1989;38:785-7.
3. Eidson M, Philen RM, Sewell CM, et al: L-tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet 1990;335:645-8.
4. Slutsker L, Hoesly FC, Miller L, et al: Eosinophilia-myalgia syndrome associated with exposure to trypthophan from a single manufacturer. JAMA 1990;264:213-7.
5. Belongia EA, Hedberg CW, Gleich GJ, et al: An investigation of the cause of the eosinophilia-myalgia syndrome associated with L-tryptophan use. N Engl J Med 1990;323:357-65.
6. Back EE, Henning KJ, Kallenbach LR, et al: Risk factors for developing eosinophilia-myalgia syndrome among L-tryptophan users in New York. J Rheumatol 1993;20:666-72.
7. Hertzman PA, Belvins WI, Mayer J, et al: Association of the eosinophilia-myalgia syndrome with the ingestion of L-tryptophan. N Engl J Med 1990;322:869-73.
8. Tracking disease the old way. Los Angeles Times, 27 Nov 1989:1.
9. The doctor's world. The New York Times, 28 Nov 1989:3.
10. "Natural" but not always safe. The Washington Post, 28 Nov 1989:Z11.
11. Nine more cases of obscure syndrome reported. Albuquerque Journal, 8 Nov 1989:1.
12. Swygert LA, Maes EF, Sewell LE, et al: Eosinophilia-myalgia syndrome - results of national surveillance. JAMA 1990, 264:1698-703.
13. Spitzer WO, Haggerty JL, Berkson L, et al: Continuing occurrence of eosinophilia-myalgia syndrome in Canada. Br J Rheumatol 1995;34:246-51.
14. Kilbourne EM, Swygert LA, Philen RM, et al: Interim guidance on the eosinophilia-myalgia syndrome. Ann Intern Med 1990;112:85-7.
15. Hibbs JR, Mittleman B, Hill P, Medsger TA Jr: L-tryptophan-associated eosinophilic fasciitis prior to the 1989 eosinophilia-myalgia syndrome outbreak. Arthritis Rheum 1992;35:299-303.